A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.

Chih-Hsi Scott KuoPi-Hung TungAllen Chung-Cheng HuangChin-Chou WangJohn Wen-Cheng ChangChien-Ying LiuFu-Tsai ChungYueh-Fu FangYi-Ke GuoCheng-Ta Yang

Published in: BMC cancer (2021)

Second-generation ALK inhibitors in crizotinib-treated patients showed a satifactory efficacy. Alectinib treatment demonstrated a CNS protection activity and a higher PFS in selected patients failing crizotinib treatment.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
epidermal growth factor receptor
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
blood brain barrier